Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...

In January this year, AstraZeneca and partner Daiichi’s drug, Datroway/datopotamab deruxtecan was approved by the FDA for HR+ HER2- breast cancer while a regulatory application is under review ...

AstraZeneca secured approvals for two new molecular entities. Kavigale received EU approval for the prevention of COVID-19 in immunocompromised people aged 12 years and older. Datroway was ...

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments in terms of progression-free survival, according to AstraZeneca.

AstraZeneca and Daiichi Sankyo have claimed ... cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a treatment for previously treated HR+/HER2- breast ...

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI), propelling the industry’s growth. Amid this backdrop, quality medical ...

The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...